Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases. Utilizing its proprietary technology, Immunovant aims to create monoclonal antibodies that target specific pathways involved in these conditions, with the goal of providing safer and more effective treatment options. The company's research and development efforts are centered on addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from autoimmune disorders. Through its commitment to scientific advancement and patient care, Immunovant actively works to bring novel treatments to the market. Read More
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster" that could sustain their independence. Today, Argenx (NASDAQ: ARGX) has effectively ended that search, cementing its status as a global biopharmaceutical powerhouse. Following its full-year 2025 earnings [...]
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a significant 15% stock surge, a move driven by clinical validation of its diversified "Vant" model. This recent rally—pushing shares toward a yearly high of $24.21—is primarily [...]
Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies.
NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws.
The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. (“Immunovant” or “the Company”) (NASDAQ: IMVT) for violations of the securities laws.
The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws.
PITTSBURGH, PA / ACCESS Newswire / June 20, 2025 / Law Office of Alfred G. Yates Jr. PC announces investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ:IMVT) and Roivant Sciences Ltd. - Immunovant's controlling stockholder - in connection with Immunovant's January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day's closing price.
Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. – Immunovant’s controlling stockholder – in connection with Immunovant’s January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day’s closing price.
Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company.
